IV iron replacement therapy

Class

IV iron replacement therapy — superparamagnetic iron oxide nanoparticle coated with a polyglucose sorbitol carboxymethylether shell, releases bioavailable iron for transferrin binding and incorporation into hemoglobin/ferritin stores

Pathway

Iron repletion / erythropoiesis substrate supply

Notes

original target text: IV iron replacement therapy — superparamagnetic iron oxide nanoparticle coated with a polyglucose sorbitol carboxymethylether shell, releases bioavailable iron for transferrin binding and incorporation into hemoglobin/ferritin stores

Iron is an essential cofactor for hemoglobin synthesis in developing red blood cells and supports many other enzymatic processes throughout the body. Adequate iron stores are a prerequisite for effective erythropoiesis, the process by which the bone marrow produces new red blood cells in response to erythropoietin. When iron is insufficient, whether from poor dietary absorption, chronic blood loss, or heightened demand, red blood cell production falters and anemia develops. Oral iron supplementation is limited by the gut's absorption capacity and is often poorly tolerated, which makes it inadequate in conditions such as chronic kidney disease, inflammatory bowel disease, and heart failure, where iron needs are elevated or intestinal absorption is impaired. Intravenous iron replacement bypasses the digestive tract entirely, delivering iron directly into the bloodstream for use by red cell precursors and for storage. To do this safely, the iron is formulated as a nanoparticle core surrounded by a carbohydrate shell that controls the rate of iron release, avoiding the toxicity associated with free ionic iron. Once released, iron binds transferrin, the body's principal iron transport protein, which carries it to the bone marrow for incorporation into hemoglobin or to storage tissues as ferritin. This mechanism is broadly relevant wherever anemia results from absolute or functional iron deficiency.